ESR1 and breast cancer: At a nationwide level in ER+/Her2− breast cancer patients, this study demonstrates a strong decrease in the administration of adjuvant chemotherapy over time without an adjustment in the national breast cancer guideline but in line with contemporary international consensus statements.